Lessee, Operating Lease, Liability, to be Paid in USD of Theravance Biopharma, Inc. from Q1 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease.
Summary
Theravance Biopharma, Inc. quarterly Lessee, Operating Lease, Liability, to be Paid history and growth rate from Q1 2019 to Q4 2024.
  • Theravance Biopharma, Inc. Lessee, Operating Lease, Liability, to be Paid for the quarter ending December 31, 2024 was $62.9M, a 4.84% decline year-over-year.
Lessee, Operating Lease, Liability, to be Paid, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, YoY Quarterly Growth (%)

Theravance Biopharma, Inc. Quarterly Lessee, Operating Lease, Liability, to be Paid (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2024 $62.9M -$3.2M -4.84% Dec 31, 2024 10-K 2025-03-07
Q4 2023 $66.1M -$16.5M -20% Dec 31, 2023 10-K 2024-03-01
Q4 2022 $82.6M -$3.42M -3.98% Dec 31, 2022 10-K 2023-03-01
Q4 2021 $86M -$15.1M -14.9% Dec 31, 2021 10-K 2022-02-28
Q4 2020 $101M -$6.24M -5.81% Dec 31, 2020 10-K 2021-02-26
Q4 2019 $107M Dec 31, 2019 10-K 2020-02-27
Q3 2019 $109M Sep 30, 2019 10-Q 2019-11-08
Q2 2019 $111M Jun 30, 2019 10-Q 2019-08-05
Q1 2019 $113M Mar 31, 2019 10-Q 2019-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.